Thieno[2,3-b]pyridine compounds potently inhibit prostate cancer growth and motility

• Published in: Endocrine oncology Vol. 5; no. 1; p. e240082
• Main Authors: Alkheilewi, M A, Leach, D A, Mohr, A, Zwacka, R M, Laissue, P, Metodiev, M, Bevan, C L, Van Rensburg, M, Pilkington, L I, Barker, D, Reynisson, J, Brooke, G N
• Format: Journal Article
• Language: English
• Published: England Bioscientifica Ltd 08.07.2025; Bioscientifica
• Subjects: multinucleation; prostate cancer; therapeutics; therapy resistance; prostate cancer; therapeutics; multinucleation; therapy resistance

Prostate cancer growth is dependent upon androgens and hence therapies often target this signalling axis. These therapies, for example the antiandrogen enzalutamide, are successful in the majority of men; however, resistance is inevitable and the tumour progresses to the castrate-resistant stage, a...